Literature DB >> 16024124

Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway.

Mahmoud Toulany1, Klaus Dittmann, Maren Krüger, Michael Baumann, H Peter Rodemann.   

Abstract

BACKGROUND AND
PURPOSE: In the context of EGFR-targeting strategies we investigated autocrine/paracrine factors leading to in vitro radioresistance of K-Ras mutated tumor cells through activation of EGFR mediated signal transduction. PATIENTS AND METHODS: Ras mutated (Rasmt) and normal Ras (Raswt) presenting human tumor cell lines were used to analyze the potential of conditioned media (CM) of both cell types to mediate radioresistance and to activate EGFR-signaling cascades. Therefore, clonogenic assays as well as SDS-PAGE combined with immunoblotting was performed. Additionally, Ras-mutated cells were transfected with K-Ras-siRNA to investigate, how downregulation of mutated K-Ras affects secretion of EGFR-ligands, stimulation of EGFR-signaling and modulation of radiation response.
RESULTS: TGFalpha, Amphiregulin (ARG) and CM from Rasmt cells (Rasmt-CM) resulted in an increased clonogenic survival of irradiated Raswt cells. Both, EGFR ligands as well as Rasmt-CM led to a strong phosphorylation of EGFR and activation of downstream pathways, i.e. PI3K-AKT. However, neutralization of TGFalpha or ARG in Rasmt-CM led to a marked reduction of P-AKT. Furthermore, Rasmt-CM from K-Ras-siRNA transfected Rasmt-cells markedly inhibited phosphorylation of AKT in Raswt cells and enhanced radiation sensitivity of A549 cells transfected with the siRNA.
CONCLUSION: The data suggest that constitutively upregulated autocrine/paracrine secretion of EGF receptor ligands, especially ARG from K-Ras mutated cells, mediates radioresistance in Rasmt-cells through stimulation of EGFR-PI3K-AKT pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024124     DOI: 10.1016/j.radonc.2005.06.024

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  36 in total

1.  FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and repair of DNA damage in cervical cancer cells.

Authors:  Sridhar Muthusami; D S Prabakaran; Jae-Ran Yu; Woo-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-24       Impact factor: 4.553

2.  Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.

Authors:  Kristin Gurtner; Zofia Kryzmien; Lydia Koi; Meng Wang; Cyril H Benes; Sandra Hering; Henning Willers; Michael Baumann; Mechthild Krause
Journal:  Int J Cancer       Date:  2019-08-19       Impact factor: 7.396

Review 3.  Biological determinants of radioresistance and their remediation in pancreatic cancer.

Authors:  Parthasarathy Seshacharyulu; Michael J Baine; Joshua J Souchek; Melanie Menning; Sukhwinder Kaur; Ying Yan; Michel M Ouellette; Maneesh Jain; Chi Lin; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-02-27       Impact factor: 10.680

4.  Expression of Smac induced by the Egr1 promoter enhances the radiosensitivity of breast cancer cells.

Authors:  Z-L Li; S Liang; Z-C Wang; Y-B Li; C-X Guo; F Fang; S-L Gong; C-H Lin
Journal:  Cancer Gene Ther       Date:  2014-03-28       Impact factor: 5.987

5.  Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.

Authors:  Ambrose R Kidd; Jared L Snider; Timothy D Martin; Sarah F Graboski; Channing J Der; Adrienne D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-07       Impact factor: 7.038

6.  EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.

Authors:  Meng Wang; Fabian Morsbach; David Sander; Liliana Gheorghiu; Akash Nanda; Cyril Benes; Malte Kriegs; Mechthild Krause; Ekkehard Dikomey; Michael Baumann; Jochen Dahm-Daphi; Jeffrey Settleman; Henning Willers
Journal:  Cancer Res       Date:  2011-08-18       Impact factor: 12.701

Review 7.  Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.

Authors:  Klaus Dittmann; Claus Mayer; H Peter Rodemann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

Review 8.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

9.  A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines.

Authors:  Piotr Jasinski; Brandon Welsh; Jorge Galvez; David Land; Pawel Zwolak; Lori Ghandi; Kaoru Terai; Arkadiusz Z Dudek
Journal:  Invest New Drugs       Date:  2007-10-24       Impact factor: 3.850

10.  Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.

Authors:  Maria J Sambade; J Terese Camp; Randall J Kimple; Carolyn I Sartor; Janiel M Shields
Journal:  Radiother Oncol       Date:  2009-10-23       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.